FilingReader Intelligence
Shanghai Pharma's salbutamol injection passes consistency evaluation
July 28, 2025 at 09:10 AM UTC•By FilingReader AI
Shanghai Pharmaceuticals Holding announced its Salbutamol Sulfate Injection has passed China's consistency evaluation for generic drugs, a key regulatory milestone.
The approval is expected to enhance the product's market competitiveness and provide greater support in medical insurance payments and hospital procurement.
According to IQVIA data, the procurement value of injectable Salbutamol Sulfate in Chinese mainland hospitals in 2024 was RMB 12,989 million.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:601607•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Shanghai Pharmaceuticals Holding publishes news
Free account required • Unsubscribe anytime